Investor Presentaiton
FUTURE FOCUS
alimera
Q Post-marketing evidence, including a pipeline of development for both products, validating
with post approval studies:
SYNCHRONICITY
STUDY
NEW DAY
STUDY
CALM STUDY
Q (Data H2 2024) - A
prospective, open label
study to assess safety and
efficacy of YUTIQ in chronic,
non-infectious uveitis
affecting the posterior
segment and intraocular
inflammation in patients
without systemic
involvement. Fully enrolled,
this is a two-year follow up
study with 6 month
readout
Nasdaq: ALIM
Q (Data Q1 2025) -
A prospective,
randomized, controlled
study and first ever
direct head-to-head
comparison of a
corticosteroid and anti-
VEGF therapy
(aflibercept); Assesses
ILUVIEN as baseline
therapy. Fully enrolled.
A retrospective registry study
to assess the real-world safety
and efficacy impact of YUTIQ
used for the treatment of
chronic non-infectious uveitis
affecting the posterior
segment on ocular
inflammation and visual
acuity, and to determine local
or systemic factors which
might predict treatment
response and identify
adverse safety events
0
FUTURE
Evaluating potential
label expansion
opportunities
16View entire presentation